Center for Scientific Review; Notice of Closed Meetings, 66731 [2024-18412]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 159 / Friday, August 16, 2024 / Notices
and Uses Thereof’’ [HHS Reference No.
E–070–2012–0–US–04];
5. Germany Patent No.
602013016154.2, filed October 30, 2014,
entitled ‘‘Derivatives Of
Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–DE–05];
6. France Patent No. 2847178, filed
October 30, 2014, entitled ‘‘Derivatives
Of Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–FR–06];
7. Great Britain Patent No. 2847178,
filed October 30, 2014, entitled
‘‘Derivatives Of Docosahexaenoylamide
and Uses Thereof’’ [HHS Reference No.
E–070–2012–0–GB–07].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Use of a G-protein-coupled receptor
110 (‘‘GPR110’’) agonist named
dimethyl synaptamide (‘‘DMS’’) (also
known as Compound NCGC00248435;
(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxy2-methylpropyl) docosa-4,7,10,13,16,19hexaenamide; or ‘‘A8’’) to treat multiple
sclerosis (‘‘MS’’), chronic inflammatory
demyelinating polyradiculoneuropathy
(‘‘CIDP’’), psoriasis, inflammatory bowel
disease (‘‘IBD’’), Crohn’s disease,
ulcerative colitis (‘‘UC’’), sclerosing
cholangitis, ankylosing spondylitis,
rheumatoid arthritis (‘‘RA’’), psoriatic
arthritis, systemic lupus erythematosus
(‘‘SLE’’), lupus nephritis, sarcoidosis,
and Behcet’s disease.’’
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the NHLBI Office
of Technology Transfer And
Development receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
VerDate Sep<11>2014
17:33 Aug 15, 2024
Jkt 262001
66731
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
Dated: August 13, 2024
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–18381 Filed 8–15–24; 8:45 am]
[FR Doc. 2024–18412 Filed 8–15–24; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
National Institute of Dental &
Craniofacial Research; Notice of
Partially Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: September 9, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael L. Bloom, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7804, Bethesda, MD 20892, 301–451–
0132, bloomm2@mail.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Biobehavioral Medicine and Health
Outcomes Study Section.
Date: September 19–20, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
Bethesda, MD 20892, (301) 402–4128,
mark.vosvick@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Dental
and Craniofacial Research Council.
The meeting will be held as a virtual
meeting and is partially open to the
public as indicated below. Individuals
who plan to view the virtual meeting
and need special assistance to view the
meeting, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting. The open session will be
videocast and can be accessed from the
NIH Videocasting website (https://
videocast.nih.gov/). Registration is not
required to access the videocast.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National
Advisory Dental and Craniofacial
Research Council.
Date: September 11, 2024.
Open: 10:00 a.m. to 3:15 p.m.
Agenda: Report of the Director,
NIDCR and concept clearances.
Place: National Institute of Dental &
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
Closed: 3:30 p.m. to 4:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental &
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 89, Number 159 (Friday, August 16, 2024)]
[Notices]
[Page 66731]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-18412]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Respiratory Sciences.
Date: September 9, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael L. Bloom, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187, MSC 7804, Bethesda, MD
20892, 301-451-0132, [email protected].
Name of Committee: Risk, Prevention and Health Behavior
Integrated Review Group; Biobehavioral Medicine and Health Outcomes
Study Section.
Date: September 19-20, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110, Bethesda, MD 20892, (301)
402-4128, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: August 13, 2024
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-18412 Filed 8-15-24; 8:45 am]
BILLING CODE 4140-01-P
